Skip to main content
. 2024 Oct 30;16(10):e72725. doi: 10.7759/cureus.72725

Table 2. Functional status outcomes for the cohort.

NYHA: New York Heart Association; SGLT2i: sodium-glucose cotransporter-2 inhibitor. * not statistically significant. A p-value <0.05 was considered statistically significant.

NYHA class P-value
  Class I (n) Class II (n) Class III (n) Class IV (n)   0.73*
Pre-SGLT2i therapy 5 10 31 7
On SGLT2i therapy 5 13 25 9